Sanofi’s Vaccine Division Files sBLA with FDA and 4 Stocks Hitting 52-Week Highs

PPG Industries (NYSE:PPG): PPG Industries reports a third quarter adjusted earnings per share of $2.24, and a consensus of $2.20. Their shares closed at $119.09, up $0.12 or 0.1% on the day. They have traded in a 52-week range of $78.29 to $120.00.

Snap-On Inc. (NYSE:SNA): Snap-On Inc. reported a third quarter earnings per share of $1.26, and a consensus $1.23. Their shares closed at $76.97, up $2.72 or 3.66% on the day. They have traded in a 52-week range of $47.91 to $74.29.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Sanofi-Aventis Sa (NYSE:SNY): Sanofi Pasteur, the vaccines division of Sanof-Aventis Sa., announced that they have filed a Supplemental Biologics License Application (sBLA) with the Federal Drug Administration for a quadrivalent formulation of their Fluzone. The sBLA file has been accepted by the FDA for full review and an action date is anticipated in the second quarter of 2013. If approved by the FDA, Fluzone Quadrivalent vaccine would be the first quadrivalent influenza vaccine for Sanofi Pasteur. Their shares closed at $45.59, up $0.51 or 1.13% on the day. They have traded in a 52-week range of $31.61 to $45.22.

Syntel (NASDAQ:SYNT): Syntel has a 2012 earnings per share of $4.36-$4.40, with a consensus $3.96. Their shares closed at $60.87, down $0.39 or 0.64% on the day. They have traded in a 52-week range of $42.62 to $64.94.

The Travelers Company (NYSE:TRV): The Travelers Company said, “We are very pleased with our strong results this quarter. Our underwriting performance reflected a GAAP combined ratio of 90.3%, which benefited from lower weather-related losses as well as the rate gains we have achieved during the past year. Net investment income benefited from strong results in our non-fixed income portfolio. We are also very pleased with our continued execution in the marketplace, noting in particular that we once again achieved written rate gains across each of our segments.” Their shares closed at $73.94, up $2.56 or 3.59% on the day. They have traded in a 52-week range of $52.51 to $71.38.

Don’t Miss: Can Pfizer Beat Competitors to TB Cure?